Click here to listen to previous episodes.
About Chen Lin
Author "What is Chen Buying? What is Chen Selling?" Chen grew $5,400 to $2.3 million in 10 years. Learn More
The Healthcare Sector’s Performance Has Zero Correlation With Earnings Estimates
From Eric Bush: Equity returns and earnings estimates should presumably be related. It makes intuitive sense that if earnings estimates are increasing for a sector than equity prices for that sector should trend upwards as well.
And this broadly holds up except oddly with the healthcare sector.
Overall for the GKCI Developed Market Index, median next 12-months EPS estimates have a 62% correlation with the year-over-year price change of the index going back to 2003. So as next 12 months EPS estimates increase, the year-over-year change in the price of the GKCI DM Index usually increases as well. For many sectors, such as for financials and industrials, earnings estimates have over a 60% correlation to the equity returns of those sectors.
However, in the case of healthcare, earnings estimate revisions actually have a -19% correlation with equity returns.
We can see the same phenomena when we look at earnings estimate revision breadth. In the charts below, we track the the percentage of stocks in each index or sector that has higher next 12 months EPS estimates than they did six months ago.
Currently 48% of GKCI DM Index constituents have higher next 12-month EPS estimates than they did six months ago. This series has a 62% correlation to year-over-year equity returns. Earnings revision breadth has a 74% correlation for the energy sector and a 69% correlation for the financial sector. Once again, healthcare is the odd sector out with basically zero correlation between earnings estimate breadth and year-over-year equity returns.
The Health Care SPDR ETF (NYSE:XLV) rose $0.06 (+0.08%) in premarket trading Wednesday. Year-to-date, XLV has gained 5.70%, versus a 4.55% rise in the benchmark S&P 500 index during the same period.
XLV currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #1 of 36 ETFs in the Health & Biotech ETFs category.
Sign up for reports from Gavekal Capital
This article is brought to you courtesy of Gavekal Capital.
You are viewing an abbreviated republication of ETF Daily News content. You can find full ETF Daily News articles on (www.etfdailynews.com)
Powered by WPeMatico